共 242 条
[1]
Fahy JV(2015)Type 2 inflammation in asthma—present in most, absent in many Nat Rev Immunol 15 57-65
[2]
Woodruff PG(2009)T-helper type 2-driven inflammation defines major subphenotypes of asthma Am J Respir Crit Care Med 180 388-395
[3]
Modrek B(2017)Revisiting type 2-high and type 2-low airway inflammation in asthma: current knowledge and therapeutic implications Clin Exp Allergy 47 161-175
[4]
Choy DF(2020)Diagnosis and management of T2-high asthma J Allergy Clin Immunol Pract. 8 442-450
[5]
Jia G(2019)Understanding asthma phenotypes, endotypes, and mechanisms of disease Clin Rev Allergy Immunol 56 219-233
[6]
Abbas AR(2017)Asthma management: a new phenotype-based approach using presence of eosinophilia and allergy Allergy Eur J Allergy Clin Immunol. 72 1279-1287
[7]
Ellwanger A(2014)International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma task force report ERS/ATS guidelines on severe asthma executive summary Eur Respir J 43 343-373
[8]
Robinson D(2011)Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma Allergy 66 671-678
[9]
Humbert M(2005)Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): iNNOVATE Allergy 60 309-316
[10]
Buhl R(2013)Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey Eur Respir J 42 1224-1233